CD274 and neoplasm: In colorectal cancer, increased mutational burden from deficient MMR (dMMR) and MSI associates with improved response to PD-1/PD-L1 blockade (92), leading to FDA approval of pembrolizumab for any dMMR/MSI tumor (93).